Scholarlink

Background <p>Mitophagy plays a vital role in hepatocellular carcinoma (HCC) progression. This study aims to construct a mitophagy-related scoring system and evaluate its prognostic value, association with tumor immune activity, and gene mutation profiles in HCC patients, thereby advancing personalized diagnosis and treatment.</p> Methods <p>Copy number variation (CNV) data of mitophagy regulators from TCGA and ICGC databases were integrated for consensus clustering. Principal component analysis (PCA) was employed to establish a mitophagy scoring system based on mitophagy clusters, gene clusters, and clinical outcomes. Kaplan-Meier survival analysis, Spearman correlation, and immune infiltration algorithms (CIBERSORT, ssGSEA) were used to assess clinical relevance, prognosis, and immunotherapy sensitivity. Tumor mutation burden (TMB) was combined with mitophagy scores for refined prognosis prediction.</p> Results <p>Three distinct mitophagy clusters (A, B, C) and gene clusters (A, B, C) were identified, showing significant differences in prognosis, immune cell infiltration (19 immune cell types, <i>p</i> &lt; 0.05), and mutation profiles. The mitophagy scoring system stratified patients into high- and low-score groups. High-score patients exhibited better overall survival (<i>p</i> &lt; 0.001), higher immune checkpoint expression (PD-1, CTLA4; <i>p</i> = 0.015 and <i>p</i> = 0.0007), and greater sensitivity to immunotherapy. Low-score patients had higher TP53 mutation rates (55%) and poorer outcomes. Combining mitophagy scores with TMB further improved prognostic accuracy (<i>p</i> &lt; 0.001).</p> Conclusion <p>The mitophagy scoring system serves as a robust prognostic biomarker and predictor of immunotherapy response in HCC, offering insights into tumor heterogeneity and clinical decision-making.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Systematic analysis of the mitophagy scoring system in the prognosis and immunotherapy of HCC patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月9日

查看全文
  • Yangjun Yin,
  • Maixuan Qiu,
  • Jun Shen,
  • Jianjun Yan

摘要

Background

Mitophagy plays a vital role in hepatocellular carcinoma (HCC) progression. This study aims to construct a mitophagy-related scoring system and evaluate its prognostic value, association with tumor immune activity, and gene mutation profiles in HCC patients, thereby advancing personalized diagnosis and treatment.

Methods

Copy number variation (CNV) data of mitophagy regulators from TCGA and ICGC databases were integrated for consensus clustering. Principal component analysis (PCA) was employed to establish a mitophagy scoring system based on mitophagy clusters, gene clusters, and clinical outcomes. Kaplan-Meier survival analysis, Spearman correlation, and immune infiltration algorithms (CIBERSORT, ssGSEA) were used to assess clinical relevance, prognosis, and immunotherapy sensitivity. Tumor mutation burden (TMB) was combined with mitophagy scores for refined prognosis prediction.

Results

Three distinct mitophagy clusters (A, B, C) and gene clusters (A, B, C) were identified, showing significant differences in prognosis, immune cell infiltration (19 immune cell types, p < 0.05), and mutation profiles. The mitophagy scoring system stratified patients into high- and low-score groups. High-score patients exhibited better overall survival (p < 0.001), higher immune checkpoint expression (PD-1, CTLA4; p = 0.015 and p = 0.0007), and greater sensitivity to immunotherapy. Low-score patients had higher TP53 mutation rates (55%) and poorer outcomes. Combining mitophagy scores with TMB further improved prognostic accuracy (p < 0.001).

Conclusion

The mitophagy scoring system serves as a robust prognostic biomarker and predictor of immunotherapy response in HCC, offering insights into tumor heterogeneity and clinical decision-making.